Ovid Therapeutics (OVID) stock

Seizure medicines , market cap $504M

Medicines for seizures and rare epilepsies

Worth $504M

Pre-market

$2.90

+1.75%

Close $2.85 +10.47%

As of 9:05 AM ET pre-market, delayed 15+ min · Live for Pro members

Quality Score

Average

In its industry

#68of 281

Biotech

Checks firing

7of 14

Trending up

From 52-week high

-8.2%

under its best in a year

OVID's Quality Score rose 7 points on Fri, Nov 6, to 6. Buying reached its highest in 20 days (4 chart checks started).

Follow OVID's news. Pro members can get an alert when Ovid Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when OVID files newsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2H 2026“…development plan, Ovid intends to initiate a ketamine challenge study of OV4071 in the second half of 2026…”Trial start · SEC filing · Aug 13

Cash$170M, about 12 quarters (3 years) at the last year's spendingOn Jun 30 · the company says “into 2029”

Why is OVID up?

Up 32% from Oct 26 to Nov 6 while the S&P 500 fell 4%.

Ovid Therapeutics rose 32% from Oct 26 to Nov 6 while biotech stocks rose a median 3%: it beat its group by 29 points.

Sources: Price history, Nov 6, 2026

How the business stands, the timeline, and its peers, for Pro members.

Key facts on OVID

Key facts on OVID
The chart	Stronger than 91% of stocks above every average
Latest filing	10-Q, Aug 13 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

1 more reason behind OVID's 6, free with an account →5 more reasons behind OVID's 6, for Pro members.

OVID in the news

ReportExpected to report Wednesday, before the open. Every 3 months, a company tells everyone how much it sold and earned. It rose after 3 of its last 4 reports, +5.5% on average. Past reports ›

What's next

Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.

2 more dates ahead: conferences, for Pro members.

Cash$170M, about 12 quarters (3 years) at the last year's spendingOn Jun 30 · the company says “into 2029”

OVID catalysts

Coming up

After its last 4 reports it closed +5.5% on average, higher 3 of 4 times.

4 past catalysts since 2020, with sizes and sources, for Pro members.

What's next for OVID, and how long its cash lasts

Next step the company has named

2H 2026“…as a part of the clinical development plan, Ovid intends to initiate a ketamine challenge study of OV4071 in the second half of 2026 to further characterize potential pharmacodynamic…”Trial start · SEC filing · Aug 13

What it means: when a trial begins, or reaches the stage the company named.

Lead program: OV4071

For Pro members: 2 more milestones and 31 filings.

Cash runway Jun 30 balance sheet

About 12 quarters

$170M in cash and investments (as the company counts them), at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into 2029” (8-K, Aug 13).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

CEO Margaret A. Alexander sold 11,656 shares on Feb 23. 1 more insider trade this year.

From Form 4: open-market buys and sales only.

Get an alert when Margaret Alexander buys or sells

For Pro members: every trade, and Margaret Alexander’s 10 filings and quotes.

Get an alert when OVID files newsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 13 daysFDA decisionIn 13 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 13 daysFDA decisionIn 13 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 43 daysFDA decisionIn 43 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why OVID scores 6

Averagefor quality, not price, 7 of 14 chart checks firingWhat the Quality Score means

+7Chart checks 7 of 14 firing right now, one point each
+3Long-term trend above a rising 200-⁠day average, near its 52-⁠week high

Run-up adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth subtractsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Size, Persistence, and News.

What every line is worth, and the reason behind it, on OVID and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 9:05 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when OVID's Quality Score turns up

A free account. No card.

How OVID ranks in Biotech

OVID is #68 of 281 by Quality Score.

How OVID ranks in Biotech
Rank	Stock	Checks	Quality Score
1	XERSXeris Biopharma	9/14	22
2	ONCBeOne Medicines	6/14	22
3	VCELVericel	8/14	21
	ORKAOruka Therapeutics		Open for its score
	OSTXOS Therapies		Open for its score
	PALIPalisade Bio		Open for its score
	PBLSParabilis Medicines		Open for its score
68	OVIDOvid Therapeutics	7/14	6

When does OVID report earnings, and what happens after?

Expected to report Wed Nov 11, before the open (in 2 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

Close after the report, last 3

+14.4%+2.9%+6.9%

Mar 18May 12Aug 13

Reported	When	Gap	Reaction	5 days
Aug 13, 2026Before open	Before open	+1.1%	+6.9%	+11.8%
May 12, 2026Before open	Before open	-0.4%	+2.9%	-13.6%
Mar 18, 2026Before open	Before open	+19.9%	+14.4%	+20.4%

OVID closed higher after 3 of its last 4 reports.

All 4 reports, and OVID's Quality Score going into each

Everyone reporting earnings this week

OVID sales and profit by year

Sales and profit by year

Sales grew in two of the last four years, to $7.3M in 2025. It made a profit in one of the five years.

OVID has 7 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on OVID, and all 14 on every stock.Get in free →

OVID RSI on Nov 6: 62.4, above its 50-day and 200-day averages

Not scored

RSI 62.4, MACD above signal, above both averages. Not scored.13 readings

The deep dive on OVID

What it does and how it makes money2 findingsAn operating loss of $42.4M in fiscal 2025, on $7.25M of sales.Annual report, filed Mar 18, 2026
What changed in its filings2 findingsA new heading in its "Risk Factors" this year: "Disruptions at the FDA and other government agencies caused by layoffs, funding shortages or global health concerns could negatively impact our business." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Mar 18, 2026, against the one of Mar 11, 2025
Who holds and trades it1 findingFor Pro members1 finding on who holds and trades OVID, for Pro members

3 more findings on OVID, each with its source, for Pro members.

OVID share count over time

1% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2024, both from one filing

Shares of OVID outstanding, as filed
Shares outstanding	As of
195.3M	Aug 11, 2026
186.6M	May 8, 2026
131.9M	Mar 16, 2026
71.2M	Nov 7, 2025

Offerings, shelves, and splits of OVID, from its filings
From its filings	Filed
Registered shares for a later sale (S-3)	Apr 21, 2026
Registered shares for a later sale (S-3)	Dec 15, 2025
Set up an at-the-market program for up to $75M of shares, about 15% of its market value	Nov 15, 2023

OVID's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Margaret A. AlexanderPresident and CEO · 1 trade
Jeremy M. LevinExecutive Chairman · no trades on file
Charles Ross CarterChief Financial Officer · no trades on file
Jeffrey A. RonaCbfo · 1 trade
Kevin Joseph FitzgeraldDirector · no trades on file
Bart FriedmanDirector · no trades on file
Stelios PapadopoulosDirector · no trades on file

See insider trades by person

Which ETFs hold OVID?

In ETFs: OVID is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Ovid Therapeutics

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

23 employeesNew York, NYovidrx.com

What Ovid Therapeutics says it competes with

“There is no one direct competitor, though there are others in the field of epilepsy who market to similar indications as we may explore.”

From its annual report, SEC filing · Mar 18, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on OVID and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move OVID's score: 8 things
4 more filings explained, a plain line each
Real-⁠time prices, no delay

See OVID's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: OVID's Quality Score is 6 (Average), #68 of 281 in Biotech.

What does OVID's Quality Score say?

OVID scores 6 today, which Breakaway calls Average. It is #68 of 281 in Biotech by Quality Score, with 7 of 14 chart checks firing. Up 32% from Oct 26 to Nov 6 while the S&P 500 fell 4%. Cash lasts about 12 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is OVID's Quality Score?

OVID scores 6 today, which Breakaway calls Average (6 to 10). That is #68 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind OVID's 6.

When does OVID report earnings?

Expected to report Wed Nov 11, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. OVID closed higher after 3 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.